FIELD: medicine.
SUBSTANCE: group of inventions relates to a method of treating primary sclerosing cholangitis (PSC) in a human subject. Method involves administering a humanized anti-CCL24 monoclonal antibody or a pharmaceutical composition thereof to a human subject in dose of 10 mg/kg or 20 mg/kg. Anti-CCL24 monoclonal antibody contains a heavy chain according to SEQ ID NO: 11 and light chain in accordance with SEQ ID NO: 12. Pharmaceutical composition for treating PSC contains 1 to 500 mg/ml of said anti-CCL24 monoclonal antibody. Also disclosed is a kit for treating PSC.
EFFECT: inventions provide clinical benefit and safety in patients with PSC, leading to an increase in the total level of CCL24 in serum compared to the initial total level of CCL24 and to a decrease in the levels of one or more markers of fibrosis or inflammation as compared to their initial level.
32 cl, 13 dwg, 7 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CD71 CONJUGATES ACTIVATED ANTIBODY-DRUG AND THEIR APPLICATION METHODS | 2018 |
|
RU2771292C2 |
| TREATMENT AND FUNCTIONAL CURE OF HIV-INFECTION WITH MONOCLONAL ANTIBODIES TO CD4 MEDIATING COMPETITIVE INHIBITION OF HIV ENTRY | 2014 |
|
RU2762315C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
| COMBINED PHARMACEUTICAL COMPOSITION FOR TREATING TUMOUR | 2020 |
|
RU2829637C2 |
| TREATMENT OF IgE-MEDIATED ALLERGIC DISEASES | 2018 |
|
RU2800765C2 |
| AGONISTIC ANTIBODY TO LEPTIN RECEPTOR FOR USE IN TREATMENT OF METABOLISM DISORDERS OR HYPOLEPTINEMIA | 2019 |
|
RU2812670C2 |
| METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENICITY USING NON-DEPLETION B-CELL INHIBITORS | 2020 |
|
RU2821892C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF | 2020 |
|
RU2745814C1 |
| SUBCUTANEOUS INJECTION OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2782950C2 |
